The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Temperature regulation == In addition to their role in weight control, dynorphins have been found to regulate body temperature. Opioid peptides were first investigated in hyperthermia, where it was found that μ-opioid receptor (MOR) agonists stimulate this response when injected into the periaqueductal gray (PAG) region of the brain. Xin et al. showed that delivery of dynorphin A1-17 (a KOR agonist) through microdialysis into the PAG region induced hypothermia in rats. The authors found that the severity of hypothermia was proportional to the dose of dynorphin A1-17 administered. Hypothermia could be prevented by administering KOR antagonist nor-BNI to the rat. Xin et al. hypothesized that while MOR agonists mediate hyperthermia, KOR agonists, such as dynorphin, mediate hypothermia. Sharma and Alm found that subjecting rats to heat (38˚C) caused dynorphins to be upregulated in the cerebral cortex, hippocampus, cerebellum, and the brain stem. Further, authors found that administration of nitric oxide synthase (NOS) inhibitors reduced dynorphin A1-17 levels in the brain and attenuated symptoms related to heat stress. Sharma and Alm concluded that hyperthermia increases dynorphin levels, which may cause damage and promote heat stress reaction. They further hypothesized that nitric oxide was part of this mechanism. Ansonoff et al. found that hypothermic effects are mediated through K1 (κ-opioid receptor 1), but not K2.
Concerns regarding the impact of vaccination in pregnancy, compounded through miss information disseminated through numerous sources including social media platforms, led to poor uptake in this group, despite evidence COVID-19 vaccination has no detrimental impact on live birth or miscarriage.
== Film and television == When it comes to portrayals in entertainment, depictions typically represent mentally ill characters as being recognizably different, often exaggerating their mannerisms and appearance to further distinguish them from normal characters. Throughout the last century of filmmaking, they have most commonly been portrayed as villains, often either the victims or perpetrators of violence, and generally dangerous.
== Structure == Bilirubin consists of an open-chain tetrapyrrole. It is formed by oxidative cleavage of a porphyrin in heme, which affords biliverdin. Biliverdin is reduced to bilirubin. After conjugation with glucuronic acid, bilirubin is water-soluble and can be excreted. Bilirubin is structurally similar to the pigment phycobilin used by certain algae to capture light energy, and to the pigment phytochrome used by plants to sense light. All of these contain an open chain of four pyrrolic rings. Like these other pigments, some of the double-bonds in bilirubin isomerize when exposed to light. This isomerization is relevant to the phototherapy of jaundiced newborns: the E,Z-isomers of bilirubin formed upon light exposure are more soluble than the unilluminated Z,Z-isomer, as the possibility of intramolecular hydrogen bonding is removed. Increased solubility allows the excretion of unconjugated bilirubin in bile. Some textbooks and research articles show the incorrect geometric isomer of bilirubin. The naturally occurring isomer is the Z,Z-isomer.
=== Fullerenes === Fullerenes and carbon nanotubes, carbon compounds with spheroidal and tubular structures, have stimulated much research into the related field of materials science. The first fullerene was discovered in 1985 by Sir Harold W. Kroto of the United Kingdom and by Richard E. Smalley and Robert F. Curl Jr., of the United States. Using a laser to vaporize graphite rods in an atmosphere of helium gas, these chemists and their assistants obtained cagelike molecules composed of 60 carbon atoms (C60) joined by single and double bonds to form a hollow sphere with 12 pentagonal and 20 hexagonal faces—a design that resembles a football, or soccer ball. In 1996 the trio was awarded the Nobel Prize for their pioneering efforts. The C60 molecule was named buckminsterfullerene (or, more simply, the buckyball) after the American architect R. Buckminster Fuller, whose geodesic dome is constructed on the same structural principles.
Sources: en.wikipedia.org
The canonical example of a ligand-binding protein is haemoglobin, which transports oxygen from the lungs to other organs and tissues in all vertebrates and has close homologs in every biological kingdom. Lectins are sugar-binding proteins which are highly specific for their sugar moieties. Lectins typically play a role in biological recognition phenomena involving cells and proteins. Receptors are highly specific binding proteins, and many hormones act by binding specifically to their receptors. Transmembrane proteins can serve as ligand transport proteins that alter the permeability of the cell membrane to small molecules and ions. The membrane alone has a hydrophobic core through which polar or charged molecules cannot diffuse. Membrane proteins contain internal channels that allow such molecules to enter and exit the cell. Many ion channel proteins are specialized to select for only a particular ion; for example, potassium and sodium channels often discriminate for only one of the two ions.
The blue whale (Balaenoptera musculus) is the largest animal that has ever lived, weighing up to 190 tonnes and measuring up to 33.6 metres (110 ft) long. The largest extant terrestrial animal is the African bush elephant (Loxodonta africana), weighing up to 12.25 tonnes and measuring up to 10.67 metres (35.0 ft) long. The largest terrestrial animals that ever lived were titanosaur sauropod dinosaurs such as Argentinosaurus, which may have weighed as much as 73 tonnes, and Supersaurus which may have reached 39 metres. Several animals are microscopic; some Myxozoa (obligate parasites within the Cnidaria) never grow larger than 20 μm, and one of the smallest species (Myxobolus szekeli) is no more than 8.5 μm when fully grown.
== Diagnosis == A diagnosis can be made by an evaluation of medical history and clinical observation. The Beighton criteria are widely used to assess the degree of joint hypermobility. DNA and biochemical studies can help identify affected people. Diagnostic tests include collagen gene-variant testing, collagen typing via skin biopsy, echocardiogram, and lysyl hydroxylase or oxidase activity, but these tests cannot confirm all cases, especially in instances of an unmapped variation, so clinical evaluation remains important. If multiple members of a family are affected, prenatal diagnosis may be possible using a DNA information technique known as a linkage study. Knowledge about EDS among all kinds of practitioners is poor. Research is ongoing to identify genetic markers for all types.
== Reception == The level's originality and tonal shift caused it to stand out to critics. GamesRadar+ journalist Alex Avard praised "We Don't Go To Ravenholm..." as an example of a horror sequence in a non-horror game, describing it as "harrowing" and a "blood-soaked frightfest". Fellow GamesRadar+ journalist Ashley Reed praised the game's inclusion of "Zombie Chopper", an achievement which forced the player to beat the entire level employing only the Gravity Gun, arguing that not using weapons forced them to think creatively about how to proceed through the level, turning to items such as saw blades as improvised weaponry and employing strategies such as fleeing the zombies before they could notice the character's presence. The level was also praised for its effective use of horror elements. Den of Geek journalist Matthew Byrd described Ravenholm as "the perfect horror level", stating that it both served as a send up of horror tropes and effectively utilized them to scare the player. Suggesting that it "just happened to be the perfect idea released at the perfect time", Byrd further stated that some elements of the level "certainly don't feel quite as groundbreaking" 15 years later as they did upon the game's release. PC Gamer journalist Andy Kelly included the game on the list of his best first-person shooter levels ever, calling it "a tense, terrifying gauntlet" and "probably the best level Valve has ever designed". Screen Rant journalist Padraig Cotter argued that the level was "arguably the game's most famous" and had a "perfect balance" of horror and action.
The Georgia Train and Equip Program (GTEP) was an American-sponsored 18-month, $64-million program aimed at increasing the capabilities of the Georgian armed forces by training and equipping four 600-man battalions with light weapons, vehicles and communications. The program enabled the US to expedite funding for the Georgian military for Operation Enduring Freedom. On 27 February 2002, the US media reported that the U.S. would send approximately two hundred United States Army Special Forces soldiers to Georgia to train Georgian troops. The program implemented President Bush's decision to respond to the Government of Georgia's request for assistance to enhance its counter-terrorism capabilities and addressed the situation in the Pankisi Gorge. The program was planned to be a 20-month long, $64 million effort. The move drew protests from many Russians. On 1 March 2002, in response to the domestic outcry, Russian president Vladimir Putin met with Georgian president Eduard Shevardnadze in Kazakhstan and pledged his support for the American military initiative. The program began in May 2002 when American special forces soldiers of the 10th Special Forces Group began training select units of the Georgian Armed Forces, including the 12th Commando Light Infantry Battalion, the 16th Mountain-Infantry Battalion, the 13th "Shavnabada" Light Infantry Battalion, the 11th Light Infantry Battalion, a mechanized company, and small numbers of Interior Ministry troops and border guards.
Sources: en.wikipedia.org
(2026). Iannucci et al. (2026) report the discovery of fossil material of a hyena belonging to the genus Crocuta from the Pirro III site (Italy), and interpret this finding as indicative of presence of Middle Pleistocene deposits at Pirro Nord. Khantemirov et al. (2026) study the morphology of teeth of late Pleistocene cave hyenas from the Tip-Tugai cave (Bashkortostan, Russia), and report differences in teeth morphology between Ural hyenas and most of the European ones which might be evidence of higher degree of adaptation to bone cracking in Ural hyenas. Evidence from the study of remains of the spotted hyena from the Pleistocene strata from the San Teodoro Cave (Sicily, Italy), indicative of slightly smaller body size of the spotted hyaenas from Sicily compared to their contemporaries from mainland Europe, is presented by Iurino et al. (2026). A nearly complete cranium of Adelphailurus kansensis, providing new information on the skull anatomy of members of this species, is described from the Hemphillian Big Sandy Formation (Arizona, United States) by Chatar & Tseng (2026). Salesa et al. (2026) study the functional anatomy of the hindlimbs of Promegantereon ogygia, and report evidence of morphological similarities to hindlimbs of the early felid Proailurus lemanensis. Evidence from the study of the neuroanatomy of Megantereon cultridens, interpreted as possibly indicative of scansorial adaptations, enhanced visual processing and preferences for closed environments, is presented by Meli et al. (2026).
While the presence of ethyl carbamate is not a sensory wine fault, the compound is a suspected carcinogen which is subjected to regulation in many countries. The compound is produced from the degradation of the amino acid arginine which is present in both grape must and released in the wine through the autolysis of dead yeast cells. While the use of urea as a source of yeast assimilable nitrogen (no longer legal in most countries) was the most common cause of ethyl carbamate in wine, both O. oeni and L. buchneri have been known to produce carbamyl phosphate and citrulline which can be precursors to ethyl carbamate formation. L. hilgardii, one of the "ferocious Lactobacillus" species, has also been suspected of contributing to ethyl carbamate production. In the United States, the Alcohol and Tobacco Tax and Trade Bureau has established a voluntary target limit of ethyl carbamate in wine to less than 15 μg/L for table wines and less than 60 μg/L for dessert wines. Biogenic amines have been implicated as a potential cause of red wine headaches. In wine, histamine, cadaverine, phenylethylamine, putrescine, and tyramine have all been detected. These amines are created by the degradation of amino acids found in grape must and left over from the breakdown of dead yeast cells after fermentation. Most LAB have the potential to create biogenic amines, even some strains of O. oeni, but high levels of biogenic amines are most often associated with species from the Lactobacillus and Pediococcus genera.
=== Bleeding disorders === Platelet-mimicking nanoparticles are under preclinical investigation for their potential to mitigate bleeding in conditions such as thrombocytopenia, coagulopathy, and von Willebrand disease. While pNPs had not previously been tested for congenital bleeding disorders, recent studies suggest their ability to enhance hemostasis in VWD type 2B and vWF-deficient conditions. In vitro experiments demonstrated that SP improved platelet recruitment and thrombus formation under thrombocytopenic and vWF-deficient conditions. In vivo studies further showed that pNPs reduced bleeding in VWD-2B mice and achieved near-complete hemostatic correction in vWF-knockout models, likely by providing a surface for platelet adhesion and fibrin deposition. The nanoparticles' stability, extended circulation time, and ability to be tailored with procoagulant molecules suggest their potential as a novel therapeutic approach for severe VWD and other bleeding disorders.
=== Schizophrenia === It has been proposed that schizophrenia may be due to an increase or a decrease in glutamate signaling, leading to abnormal excitatory signaling in the prefrontal cortex region of the brain. Glutamate release by astrocytes has been linked to the synchrony of neurons in the hippocampus and cortex. A decrease in system Xc- activity may result in an increase in synaptic glutamate and a decrease in extrasynaptic glutamate. Administration of N-acetylcysteine leads to an increase in extrasynaptic NMDA receptor activation, suggesting that glutamate released from system Xc- may cause the activation of extrasynaptic NMDA receptors. A decrease in system Xc- activity may cause a decrease in the activation of extrasynaptic NMDA receptors due to either a decrease in extrasynaptic Glutamate levels or a decrease in glutathione levels after the decrease in cystine transport. On the other hand, a decrease in system Xc- activity may lead to an increase in the activation of synaptic NMDA receptors due to the decrease in activation of Group 2 mGluRs. A decrease in nonvesicular release of glutamate leads to an increase in expression of postsynaptic glutamate receptors, such as NMDA receptors. A disruption in nonvesicular glutamate release may affect synapse formation, lead to altered release of neurotransmitters, and could even disturb cortical migration during development. All of these seem to be associated with schizophrenia.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.